$KYMR · Kymera Therapeutics, Inc. SEC Filings
Position Tracker tracks 2 SEC EDGAR filings for Kymera Therapeutics, Inc. ($KYMR) from October 29, 2026 through October 29, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 1 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$KYMR 10-Q — Kymera Therapeutics, Inc.
Kymera's STAT6 program is the highest-conviction asset in targeted protein degradation; the 2x R&D ramp signals pivotal data is approaching, but the $0 quarterly revenue exposes…
$KYMR 8-K — Kymera Therapeutics, Inc.
Kymera delivered positive first-in-human data for its second major immunology degrader (KT-579) while teeing up a binary catalyst for its lead STAT6 program (KT-621) within two…